20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BlossomHill Therapeutics, Inc. Common Stock (BLSM) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 69 employees. Its market capitalization is roughly $437 million. In the fiscal year ended 2025-12-31, BLSM reported $0M in revenue and ($61M) in net income.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($72M) | ($64M) | ($36M) |
| Operating Margin % | — | — | — |
| Net Income | ($68M) | ($61M) | ($31M) |
| Net Margin % | — | — | — |
| EBITDA | — | ($64M) | ($36M) |
| Earnings Per Share (EPS) | — | $-2.08 | $-1.06 |
| Shares Outstanding (M) | 27M | 29M | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($25M) | ($22M) | ($14M) | ($11M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($24M) | ($21M) | ($13M) | ($10M) |
| Net Margin % | — | — | — | — |
| EBITDA | ($25M) | ($22M) | — | ($11M) |
| Earnings Per Share (EPS) | $-0.88 | $-0.72 | — | $-0.36 |
| Shares Outstanding (M) | 27M | 29M | — | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($64M) | ($47M) | ($31M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M |
| Free Cash Flow (FCF) | ($65M) | ($48M) | ($32M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($23M) | ($21M) | ($9M) | ($11M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | ($23M) | ($21M) | ($10M) | ($11M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $124M | $163M | $107M |
| Cash & Cash Equivalents | $95M | $137M | $100M |
| Total Liabilities | $42M | $295M | $180M |
| Total Debt (Short + Long-Term) | $1M | $0M | $1M |
| Total Shareholders' Equity | $82M | ($132M) | ($73M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BLSM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms